Dianthus Property Plant Equipment vs Short Term Debt Analysis
DNTH Stock | 28.01 0.15 0.54% |
Dianthus Therapeutics financial indicator trend analysis is much more than just examining Dianthus Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Dianthus Therapeutics is a good investment. Please check the relationship between Dianthus Therapeutics Property Plant Equipment and its Short Term Debt accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.
Property Plant Equipment vs Short Term Debt
Property Plant Equipment vs Short Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Dianthus Therapeutics Property Plant Equipment account and Short Term Debt. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Dianthus Therapeutics' Property Plant Equipment and Short Term Debt is 0.84. Overlapping area represents the amount of variation of Property Plant Equipment that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Dianthus Therapeutics, assuming nothing else is changed. The correlation between historical values of Dianthus Therapeutics' Property Plant Equipment and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Property Plant Equipment of Dianthus Therapeutics are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Property Plant Equipment i.e., Dianthus Therapeutics' Property Plant Equipment and Short Term Debt go up and down completely randomly.
Correlation Coefficient | 0.84 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Property Plant Equipment
Short Term Debt
Most indicators from Dianthus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Dianthus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.As of now, Dianthus Therapeutics' Sales General And Administrative To Revenue is increasing as compared to previous years. The Dianthus Therapeutics' current Enterprise Value Over EBITDA is estimated to increase to 1.72, while Selling General Administrative is projected to decrease to under 14.9 M.
2021 | 2023 | 2024 (projected) | Interest Expense | 3.6M | 4.1M | 2.7M | Depreciation And Amortization | 2.0M | 355K | 337.3K |
Dianthus Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Dianthus Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Dianthus Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 161.5M | 161.6M | 9.5M | 83.1M | 179.4M | 112.5M | |
Other Current Liab | 11.3M | 7.7M | 4.0M | 6.6M | 6.5M | 6.5M | |
Total Current Liabilities | 14.1M | 11.4M | 5.4M | 8.2M | 9.6M | 9.0M | |
Total Stockholder Equity | 141.2M | 143.9M | (17.2M) | (44.4M) | 168.9M | 177.3M | |
Property Plant And Equipment Net | 9.9M | 8.3M | 33K | 956K | 800K | 760K | |
Net Debt | (65.1M) | (58.2M) | (7.6M) | (14.6M) | (131.7M) | (125.2M) | |
Retained Earnings | (179.5M) | (254.4M) | (17.4M) | (45.9M) | (89.4M) | (93.9M) | |
Accounts Payable | 2.8M | 3.8M | 1.4M | 1.2M | 2.6M | 2.3M | |
Cash | 65.1M | 58.2M | 7.6M | 15.4M | 132.3M | 138.9M | |
Non Current Assets Total | 11.7M | 10.1M | 63K | 1.1M | 2.0M | 1.9M | |
Cash And Short Term Investments | 145.7M | 148.8M | 7.6M | 75.5M | 173.7M | 103.1M | |
Common Stock Shares Outstanding | 2.3M | 2.7M | 3.4M | 874.2K | 5.2M | 2.8M | |
Liabilities And Stockholders Equity | 161.5M | 161.6M | 9.5M | 83.1M | 179.4M | 112.5M | |
Other Current Assets | 4.1M | 2.7M | 10K | 53K | 3.3M | 1.9M | |
Other Stockholder Equity | 320.6M | 398.3M | 114K | (116.4M) | 78.8M | 93.4M | |
Total Liab | 20.3M | 17.7M | 26.7M | 127.5M | 10.5M | 10.0M | |
Total Current Assets | 149.8M | 151.5M | 9.4M | 82.0M | 177.5M | 107.1M | |
Accumulated Other Comprehensive Income | 8K | (23K) | (30K) | (161K) | 47K | 49.4K | |
Common Stock | 39K | 49K | 59K | 61K | 15K | 14.3K | |
Non Currrent Assets Other | 1.8M | 1.0 | (1.8M) | 61K | 1.1M | 1.1M | |
Short Term Investments | 80.7M | 90.7M | 45.3M | 60.1M | 41.4M | 53.6M | |
Non Current Liabilities Total | 6.2M | 6.3M | 21.3M | 119.3M | 904.0K | 858.8K |
Currently Active Assets on Macroaxis
When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.93) | Revenue Per Share 0.2 | Quarterly Revenue Growth 0.923 | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.